Inflammatory mediators and the destruction of bone

Bone is remodelled by the coordinated actions of osteoclasts and osteoblasts. Cellular remodelling occurs in discrete packets of bone, and is regulated by local cytokines produced in the environment of the remodelling cells. These cytokines are secreted by immune cells and by bone cells. In addition, some growth regulatory factors are incorporated into the noncollagenous bone matrix and are released in an active form when bone is stimulated to resorb. Complex interactions between these cytokines and their target cells are responsible for the normal delicate balance between bone resorption and bone formation, and disorders of bone loss are due to imbalances between the rates of resorption and formation.     

T3期胃癌CD34与新生血管形成及淋巴结转移的关系

目的研究T3期胃癌CD34与胃癌新生血管形成及淋巴结转移的关系.方法随机选取胃癌手术标本41例,其中T3N0M020例,T3N1M021例,分别进行特异性抗体免疫组化染色,并采用Image Pro Plus 5.0图像软件分析数据,计算胃癌组织CD34微血管密度(MVD)和其他相关抗体(CD44、Ⅳ型胶原、层黏蛋白)的表达,并进行统计学分析.结果CD34 MVD计数(CD34表达强度),在T3N0M0和T3N1 M0肿瘤组分别为43.10±18.22和56.24±28.36,两组比较有显著差异(P＜0.05);CD44、Ⅳ型胶原、层黏连蛋白的表达强度,T3N0M0和T3N1M0肿瘤组比较无显著差异(P＞0.05).结论CD34与T3期胃癌组织新生血管形成及淋巴结转移的关系密切,可作为诊断T3期胃癌淋巴结转移的参考指标.     

CT多平面重组显示镫骨的方法及应用价值

目的探讨利用螺旋CT多平面重组(mu ltip lanar reform ation,MPR)技术显示镫骨整体结构的方法和临床价值。方法对50例无耳症状、体征的志愿者行平行枕眶线扫描,应用轴位图像行多方位的MPR。比较轴位MPR、冠状位MPR、矢状位MPR和镫骨斜位MPR显示镫骨整体结构的差异。测量镫骨斜位图像显示层面在轴位定位图像上与矢状面的夹角,在冠状位定位图像上与矢状面的夹角。先天性镫骨异常31例,全部病例经电测听检查均表现有不同程度的传音性耳聋,均行听骨链重建术。结果正常组轴位、冠状位、矢状位均未能显示镫骨弓的整体形态,镫骨斜位MPR图像均直观显示了镫骨弓的整体形态和结构。在轴位定位图像上,镫骨斜位MPR图像显示层面与矢状面的夹角为36°±8°,在冠状位定位图像上与矢状面的夹角为57°±6°。异常组31例,其中一侧小腿缺如3例;镫骨弓不发育3例;镫骨底板增厚与周围骨融合16例;镫骨底板上结构(小头、颈、小腿)完全缺如9例,斜位MPR图像均直观显示其病理改变,轴位、冠状位以及矢状位图像均不能准确显示镫骨发育不良的病理改变。结论镫骨斜位MPR图像,能显示正常镫骨整体结构和镫骨异常改变,对听骨链重建术的术前评价具有重要意义。     

Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group

BACKGROUND: Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices. PATIENTS AND METHODS: A pain management protocol was developed based on accepted guidelines. After baseline assessment, oncology practices were randomly assigned to 'analgesic protocol' (AP) sites, where oncologists implemented the guidelines in a group of lung or prostate cancer patients, or to 'physician discretion' (PD) sites, where customary treatment was continued. Patients treated on protocol and a comparison group of patients with pain due to breast cancer or myeloma were monitored for change in pain using the Brief Pain Inventory, and for change in other symptoms or mood. RESULTS: The protocol terminated early because of poor accrual. We compared groups using proportions of patients who had no or mild pain at follow-up. Although measures of protocol adherence did not suggest the occurrence of major practice change, the proportion of lung or prostate cancer patients with no or mild pain increased significantly from baseline for those treated at AP sites compared with those treated at PD sites. There was no significant difference between the breast and myeloma patients treated at AP sites versus those treated at PD sites. CONCLUSION: A protocol for cancer pain management can improve pain control. Diffusion of these benefits to other patients was not confirmed. Given the small sample size, these findings require confirmation in a larger trial.     

Impact of lymph node metastasis on survival in patients with pathological T1 carcinoma of the ampulla of vater

To determine the prognostic factors for patients with pathological T1 (pT1) carcinoma of the ampulla of Vater, 36 consecutive patients with carcinoma of the ampulla of Vater who underwent surgery were retrospectively analyzed in terms of clinicopathological features. The overall 5-year Kaplan-Meier survival in all patients was 50.2%, and the median survival of all patients was 64.0 months. Factors favorably influencing a long-term outcome were the absence of lymph node metastasis (P<0.0001), the absence of ulcer formation of the tumor (P=0.0062), and the absence of tumor invasion into the duodenum (P = 0.0025) and the pancreas (P=0.0098). In a multivariate analysis, lymph node metastasis was the only predictor of survival (P=0.0023). In the pT1 stage patients, 20% of the patients had lymph node metastasis, and their survival was statistically poor compared to the pT1 patients without lymph node metastasis (P=0.017). As for survival after the operation, there was no significant difference between pancreatoduodenectomy and pylorus-preserving pancreatoduodenectomy.     

严重Ⅱ型糖尿病人在直肠癌晚期空腹血糖转正常1例报告

1病例报告 病人男性，52岁，住院号：101642。患原发性2型糖尿病11年，曾因吃杨梅出现了“糖尿病酮症酸中毒昏迷”在我院抢救成功1次，当时体重达85kg，身高165cm，血糖最高〉20mmol／L。近5年来，予控制饮食及口服降糖药治疗，体重维持在80kg左右，空腹血糖仍高，一般在8～12mmol／L。因渐进性便秘1年，服用肠清茶不再有效，B超发现肝脏多发占位性病变，大小约直径25mm不等。肠镜示：距肛缘约12cm处见巨大浸润肿块，表面高低不平，有糜烂出血，质脆，占肠腔全周，形成狭窄，肠镜不能通过，于2005年2月4日入院，入院时T37．2℃，P72次／min，R18次／min，BP110／70mmHg，体重65kg，身高165cm，甘油三酯0．8mmol/L，胆固醇3．2mmol/L，空腹血糖5．0mmol／L。肝脏CT示：多发性低密度结节灶，直径大小25mm左右，考虑肝内多发转移瘤。     

In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain.

Metastasis (the spread of cancer from a primary tumor to secondary organs) is responsible for most cancer deaths. The ability to follow the fate of a population of tumor cells over time in an experimental animal would provide a powerful new way to monitor the metastatic process. Here we describe a magnetic resonance imaging (MRI) technique that permits the tracking of breast cancer cells in a mouse model of brain metastasis at the single-cell level. Cancer cells that were injected into the left ventricle of the mouse heart and then delivered to the brain were detectable on MR images. This allowed the visualization of the initial delivery and distribution of cells, as well as the growth of tumors from a subset of these cells within the whole intact brain volume. The ability to follow the metastatic process from the single-cell stage through metastatic growth, and to quantify and monitor the presence of solitary undivided cells will facilitate progress in understanding the mechanisms of brain metastasis and tumor dormancy, and the development of therapeutics to treat this disease.     

乳腺癌患者血清Leptin和VEGF的表达

目的：研究瘦素（Leptin）、血管内皮生长因子（VEGF）在乳腺癌患者血清中的表达，探讨其在乳腺癌诊断中的意义。方法：选择乳腺癌患者36例，乳腺良性增生病变患者31例，另选56例健康女性作为对照。分别用放射免疫分析（RIA）和酶联免疫吸附试验（ELISA）测定这些患者术前血清Leptin、VEGF。结果：正常对照组与良性病变组、乳腺癌组Leptin存在明显差异，正常对照组与乳腺癌组，良性病变组与乳腺癌组VEGF存在明显差异。乳腺癌患者术前血清Leptin、VEGF含量与有无淋巴结转移具有相关性。结论：乳腺癌患者术前血清Leptin、VEGF可作为鉴别乳腺良恶性肿瘤有无转移的指标。     

小鼠宫颈癌腹水瘤U_(14)及其亚株侵袭特性的初步研究

本文将小鼠宫颈癌腹水瘤u_(14)和经本教研室活体筛选出的倾向于肺转移的u_(14)A-P_(11)和倾向于淋巴转移的u_(14)-AL_(10)两亚株,用鸡胚绒毛尿囊膜接种的体内方法和与经胰酶不同处理的BALB/C小鼠腹膜组织共同培养的体外方法,对三种瘤细胞的侵袭特性进行研究。结果证明,三种瘤细胞体内转移倾向的差异与其对鸡胚绒毛尿囊膜基质和小鼠腹膜基质的侵袭能力成正相关,表明瘤细胞转移的器官倾向性与瘤细胞的侵袭力有一定的关系。     

Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment

Summary The clinical and biochemical effects of combined treatment with the two aromatase inhibitors aminoglutethimide and 4-hydroxyandrostenedione were evaluated in 10 patients suffering from advanced breast cancer. All patients had become resistant to treatment with one of the drugs before having combined treatment. Seven patients progressing on 4-hydroxyandrostenedione who had aminoglutethimide added to their treatment and achieved a further suppression of plasma oestradiol by a mean of 40.0% (p<0.05). Plasma oestrone was suppressed by a mean of 40.6% (p<0.025) and plasma oestrone sulphate was suppressed by a mean of 63.6% (p<0.025). Two of the patients, neither of whom had responded to 4-hydroxyandrostenedione alone, experienced objective tumour regression when aminoglutethimide was given in concert. Three patients progressing on aminoglutethimide who had 4-hydroxyandrostenedione added showed no further suppression of their plasma oestrogen levels, and no tumour regression was observed. These findings suggest a dose-response relationship between plasma oestrogen suppression at low postmenopausal levels and objective tumour response in breast cancer.